Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolite 3,4-methylenedioxyamphetamine (MDA)

Toxicology and Applied Pharmacology

Volumn 241, Issue 3, 2009, Pages 339-347

  Fonsart, Julien ^a,b,c,d   Menet, Marie Claude ^a   Debray, Marcel ^a,b,c   Hirt, Déborah ^a,b,c   Noble, Florence ^a,b,c   Scherrmann, Jean Michel ^a,b,c   Declèves, Xavier ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CNRS   (France)

^c INSERM   (France)

^d HÔPITAL LARIBOISIÈRE   (France)

Author keywords

Ecstasy; Gender; MDA; MDMA; Pharmacokinetics; Sex

Indexed keywords

3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE;

ACCURACY; ACUTE TOXICITY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DEMETHYLATION; DISTRIBUTION VOLUME; FEMALE; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; METABOLITE; NONHUMAN; RAT; SEX DIFFERENCE; STEADY STATE; URINARY EXCRETION; URINE LEVEL;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; AREA UNDER CURVE; BIOTRANSFORMATION; CALIBRATION; CHROMATOGRAPHY, LIQUID; FEMALE; HALLUCINOGENS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; QUALITY CONTROL; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS;

RATTUS; RODENTIA;

EID: 70350608139     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2009.09.008     Document Type: Article

References (37)

1. Allott K., and Redman J. Are there sex differences associated with the effects of ecstasy/3,4-methylenedioxymethamphetamine (MDMA)?. Neurosci. Biobehav. Rev. 31 (2007) 327-347
2. Banks M.L., Sprague J.E., Kisor D.F., Czoty P.W., Nichols D.E., and Nader M.A. Ambient temperature effects on 3,4-methylenedioxymethamphetamine-induced thermodysregulation and pharmacokinetics in male monkeys. Drug Metab. Dispos. 35 (2007) 1840-1845
3. Becker J.B., Molenda H., and Hummer D.L. Gender differences in the behavioral responses to cocaine and amphetamine. Implications for mechanisms mediating gender differences in drug abuse. Ann. N.Y. Acad. Sci. 937 (2001) 172-187
4. Cadet J.L., Ladenheim B., Baum I., Carlson E., and Epstein C. CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA). Brain Res. 655 (1994) 259-262
5. Carroll M.E., Lynch W.J., Roth M.E., Morgan A.D., and Cosgrove K.P. Sex and estrogen influence drug abuse. Trends Pharmacol. Sci. 25 (2004) 273-279
6. Cho A.K., Hiramatsu M., Distefano E.W., Chang A.S., and Jenden D.J. Stereochemical differences in the metabolism of 3,4-methylenedioxymethamphetamine in vivo and in vitro: a pharmacokinetic analysis. Drug Metab. Dispos. 18 (1990) 686-691
7. Dafters R.I. Effect of ambient temperature on hyperthermia and hyperkinesis induced by 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") in rats. Psychopharmacology (Berl) 114 (1994) 505-508
8. Dafters R.I. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 58 (1995) 877-882
9. de la Torre R., Farre M., Roset P.N., Pizarro N., Abanades S., Segura M., Segura J., and Cami J. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26 (2004) 137-144
10. De Souza I., Kelly J.P., Harkin A.J., and Leonard B.E. An appraisal of the pharmacological and toxicological effects of a single oral administration of 3,4-methylenedioxymethamphetamine (MDMA) in the rat. Pharmacol. Toxicol. 80 (1997) 207-210
11. Fitzgerald R.L., Blanke R.V., and Poklis A. Stereoselective pharmacokinetics of 3,4-methylenedioxymethamphetamine in the rat. Chirality 2 (1990) 241-248
12. Fonsart J., Menet M.C., Decleves X., Galons H., Crete D., Debray M., Scherrmann J.M., and Noble F. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Toxicol. Appl. Pharmacol. 230 (2008) 117-125
13. Gandhi M., Aweeka F., Greenblatt R.M., and Blaschke T.F. Sex differences in pharmacokinetics and pharmacodynamics. Annu. Rev. Pharmacol. Toxicol. 44 (2004) 499-523
14. Gordon C.J., Watkinson W.P., O'Callaghan J.P., and Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on autonomic thermoregulatory responses of the rat. Pharmacol. Biochem. Behav. 38 (1991) 339-344
15. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev. 55 (2003) 463-508
16. Horbach G.J., Van Asten J.G., Rietjens I.M., Kremers P., and Van Bezooijen C.F. The effect of age on inducibility of various types of rat liver cytochrome P-450. Xenobiotica 22 (1992) 515-522
17. Jones D.C., Duvauchelle C., Ikegami A., Olsen C.M., Lau S.S., de la Torre R., and Monks T.J. Serotonergic neurotoxic metabolites of ecstasy identified in rat brain. J. Pharmacol. Exp. Ther. 313 (2005) 422-431
18. Koenig J., Lazarus C., Jeltsch H., Ben Hamida S., Riegert C., Kelche C., Jones B.C., and Cassel J.C. MDMA (ecstasy) effects in pubescent rats: males are more sensitive than females. Pharmacol. Biochem. Behav. 81 (2005) 635-644
19. Kuwayama K., Inoue H., Kanamori T., Tsujikawa K., Miyaguchi H., Iwata Y.T., Miyauchi S., and Kamo N. Analysis of amphetamine-type stimulants and their metabolites in plasma, urine and bile by liquid chromatography with a strong cation-exchange column-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 867 (2008) 78-83
20. Liechti M.E., Gamma A., and Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl) 154 (2001) 161-168
21. Lofgren S., Hagbjork A.L., Ekman S., Fransson-Steen R., and Terelius Y. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34 (2004) 811-834
22. McGill University Animal Care Committee. Blood collection-rodents (SOP UACC#1) (2005), McGill University, Montreal
23. McKenna C. Ecstasy is low in league table of major causes of deaths. Bmj 325 (2002) 296
24. Mechan A., Yuan J., Hatzidimitriou G., Irvine R.J., McCann U.D., and Ricaurte G.A. Pharmacokinetic profile of single and repeated oral doses of MDMA in squirrel monkeys: relationship to lasting effects on brain serotonin neurons. Neuropsychopharmacology 31 (2006) 339-350
25. Meibohm B., Beierle I., and Derendorf H. How important are gender differences in pharmacokinetics?. Clin. Pharmacokinet. 41 (2002) 329-342
26. Mueller M., Peters F.T., Ricaurte G.A., and Maurer H.H. Validated liquid chromatographic-electrospray ionization mass spectrometric assay for simultaneous determination of 3,4-methylenedioxymethamphetamine and its metabolites 3,4-methylenedioxyamphetamine, 3,4-dihydroxymethamphetamine, and 4-hydroxy-3-methoxymethamphetamine in squirrel monkey plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 855 (2007) 262-270
27. Mugford C.A., and Kedderis G.L. Sex-dependent metabolism of xenobiotics. Drug Metab. Rev. 30 (1998) 441-498
28. Nedelman J.R., and Jia X. An extension of Satterthwaite's approximation applied to pharmacokinetics. J. Biopharm. Stat. 8 (1998) 317-328
29. Palenicek T., Votava M., Bubenikova V., and Horacek J. Increased sensitivity to the acute effects of MDMA ("ecstasy") in female rats. Physiol. Behav. 86 (2005) 546-553
30. Reneman L., Schilt T., de Win M.M., Booij J., Schmand B., van den Brink W., and Bakker O. Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users. J. Psychopharmacol. 20 (2006) 389-399
31. Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl) 173 (2004) 242-248
32. Segura M., Ortuno J., Farre M., McLure J.A., Pujadas M., Pizarro N., Llebaria A., Joglar J., Roset P.N., Segura J., and de La Torre R. 3,4-Dihydroxymethamphetamine (HHMA). A major in vivo 3,4-methylenedioxymethamphetamine (MDMA) metabolite in humans. Chem. Res. Toxicol. 14 (2001) 1203-1208
33. Shah V.P., Midha K.K., Findlay J.W., Hill H.M., Hulse J.D., McGilveray I.J., McKay G., Miller K.J., Patnaik R.N., Powell M.L., Tonelli A., Viswanathan C.T., and Yacobi A. Bioanalytical method validation-a revisit with a decade of progress. Pharm. Res. 17 (2000) 1551-1557
34. Thrivikraman K.V., Huot R.L., and Plotsky P.M. Jugular vein catheterization for repeated blood sampling in the unrestrained conscious rat. Brain Res. Brain Res. Protoc. 10 (2002) 84-94
35. Tomita M., Nakashima M.N., Wada M., and Nakashima K. Sensitive determination of MDMA and its metabolite MDA in rat blood and brain microdialysates by HPLC with fluorescence detection. Biomed. Chromatogr. 21 (2007) 1016-1022
36. UNODC, 2007. World Drug Report, pp. 275. United Nations.
37. Winstock A.R., Wolff K., and Ramsey J. Ecstasy pill testing: harm minimization gone too far?. Addiction 96 (2001) 1139-1148